Unión Europea - español - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - el herpes zoster - vacunas - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. el uso de shingrix debe estar en conformidad con las recomendaciones oficiales.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - lenalidomida - mieloma múltiple - inmunosupresores - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva b.v. - carmustina - polvo y disolvente para concentrado para soluciÓn para perfusiÓn - 100 mg - carmustina 100 mg - carmustina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios tillomed spain s.l. - carmustina - polvo y disolvente para soluciÓn para perfusiÓn - 100 mg - carmustina 100 mg - carmustina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

janssen-cilag, s.a. - epoetina alfa - excipientes: - otros preparados antianÉmicos - otros preparados antianémicos - eritropoyetina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

janssen-cilag, s.a. - epoetina alfa - excipientes: - otros preparados antianÉmicos - otros preparados antianémicos -

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ucb pharma s.a. - ferroglicina sulfato - cÁpsula dura gastrorresistente - 100 mg - ferroglicina sulfato 100 mg - ferroso glicina sulfato

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ucb pharma s.a. - ferroglicina sulfato - cÁpsula dura gastrorresistente - 100 mg - ferroglicina sulfato 100 mg - ferroso glicina sulfato

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

amgen europe b.v. - filgrastim - excipientes: acetato sodico,polisorbato 80,sorbitol - inmunoestimulantes - factores estimulantes de colonias - filgrastim

Unión Europea - español - EMA (European Medicines Agency)

sandoz gmbh - epoetina alfa - anemia; kidney failure, chronic - preparaciones antianémicas - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. cardiovascular, pre-existente de la anemia en el inicio de la quimioterapia).